Tr1X Bets on the “Other” Treg. CAR-Tr1 Cells Are Coming for MS Next.
Tr1X presents engineered Tr1 regulatory T cell data for TRX103 in GvHD and CAR-Tr1 TRX319 in multiple sclerosis.
Category Voyager Articles
Avista’s AI Capsids Are Heading to the Eye and the CSF
Avista Therapeutics presents AI-designed AAV capsid platform with ATX002 for ophthalmology at ASGCT 2026 and ARVO.
AviadoBio Just Bought Its Way Across the Blood-Brain Barrier
AviadoBio licenses Apertura's TfR1 CapX BBB-crossing AAV capsid for AVB-406 tauopathy gene therapy program.
Siren Finally Tells Us What’s Inside SRN-101. It’s Interferon-Beta.
Siren Biotechnology reveals SRN-101 is an AAV9-delivered interferon-beta therapy for high-grade glioma.
Cancer Cachexia Has Zero Approved Drugs. CatalYm Just Dosed 518 Patients.
CatalYm doses first patient in 518-person Phase 2/3 VINCIT trial of visugromab for cancer cachexia.
Intellia Almost Broke 18 Months Ago. Now It’s Filing the First In Vivo CRISPR BLA.
Intellia's lonvo-z hits Phase 3 primary in HAE; rolling BLA initiated for the first systemic in vivo CRISPR therapy.
Insilico’s 30th AI-Designed Drug Came Out of Abu Dhabi
Insilico Medicine nominates ISM0387, an AI-designed PRMT5 inhibitor, as its 30th preclinical candidate and first from its UAE team.
Cellenkos Has Five Treg Programs Running. Aplastic Anemia Just Got Its Phase 2.
Cellenkos gets FDA clearance to start Phase 2 of CK0801 cord-blood Treg therapy in transfusion-dependent aplastic anemia.
Ajax Dosed Its First Patient 18 Months Ago. Lilly Just Paid $2.3B.
Lilly acquires Ajax Therapeutics for up to $2.3B before Phase 1 readout, betting on a Type II JAK2 inhibitor.
Epitopea Is Mining Junk DNA for Tumor Antigens. The MHRA Just Said Go.
Epitopea received MHRA clearance to start OVACT Phase 1/1b of CryptiVax-1001 in advanced ovarian cancer.